Literature DB >> 6425065

Role of metallothionein in cellular uptake and disposition of gold sodium thiomalate.

R P Sharma.   

Abstract

Rat liver and kidney tissue uptake of gold and its localization in the cytosol was studied following various doses of gold sodium thiomalate (GST). The timecourse of gold incorporation into intracellular gold-binding ligands following repeated injections of GST was also investigated (11 injections, one dose/week). Results show that between 30 and 60% of the hepatic and renal gold was localized in the cytosol over a wide range of GST doses. This was also true following repeated doses. In the kidney, the binding of gold to high molecular weight (HMW) proteins was saturated after the third GST dose, while incorporation into the metallothioneins (MT) continued to increase, accounting for as much as 50% of cytosolic gold. On the other hand the binding to hepatic MT was about 10x lower, and the proportion of cytosolic gold incorporated into the MT, decreased from 30% (after first 3 GST injections) to about 15% (following the last 3 injections). The results show that the stimulation of MT biosynthesis in different tissues as a response to the injected GST is not the same and varies within each organ with the dose and/or the duration of repeated exposure. In the liver, the ability of gold to induce MT synthesis was limited and the importance of MT in the cellular uptake and disposition of gold may largely be confined to the kidneys. It is suggested that besides playing a possible role in the detoxification of cellular gold, particularly in the kidney, MT may also contribute towards the retention and localization of gold in the tissues.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6425065     DOI: 10.1007/BF03189605

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  19 in total

1.  The subcellular distribution of gold in monkey liver, kidney and spleen, in vivo.

Authors:  R P Sharma; E G McQueen
Journal:  Clin Exp Pharmacol Physiol       Date:  1979 Sep-Oct       Impact factor: 2.557

2.  Alterations induced in heme pathway enzymes and monooxygenases by gold.

Authors:  J L Eiseman; A P Alvares
Journal:  Mol Pharmacol       Date:  1978-11       Impact factor: 4.436

3.  Gold Therapy in Rheumatoid Arthritis: Final Report of a Multicentre Controlled Trial.

Authors: 
Journal:  Ann Rheum Dis       Date:  1961-12       Impact factor: 19.103

4.  Studies with radioactive gold.

Authors:  J S LAWRENCE
Journal:  Ann Rheum Dis       Date:  1961-12       Impact factor: 19.103

5.  Preventive mechanism of spironolactone against mercury-induced renal damage: role of metallothionein.

Authors:  H Takahashi; Y Shibuya
Journal:  Toxicol Appl Pharmacol       Date:  1979-02       Impact factor: 4.219

6.  Differential induction by cadmium of a low-complexity ribonucleic acid class in cadmium-resistant and cadmium-sensitive mammalian cells.

Authors:  J K Griffith; M D Enger; C E Hildebrand; R A Walters
Journal:  Biochemistry       Date:  1981-08-04       Impact factor: 3.162

7.  Metabolism of intracellular zinc and copper following single and repeated injections of gold sodium thiomalate.

Authors:  R P Sharma
Journal:  Agents Actions       Date:  1983-06

8.  The binding of gold to cytosolic proteins of the rat liver and kidney tissues: metallothioneins.

Authors:  R P Sharma; E G McQueen
Journal:  Biochem Pharmacol       Date:  1980-07-15       Impact factor: 5.858

9.  Inhibition of adenosine triphosphatases by gold.

Authors:  B R Nechay
Journal:  Arthritis Rheum       Date:  1980-04

10.  The tissue distribution of gold, copper and zinc in animals treated with Au (III); species differences in the binding of these metals in the kidney.

Authors:  E M Mogilnicka; M Webb
Journal:  J Appl Toxicol       Date:  1981-02       Impact factor: 3.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.